BioSpace News Archive

Business

Aduro Biotech Reports Third Quarter 2017 Financial Results

Net loss for the third quarter of 2017 was $24.5 million, or $0.33 per share.

November 1, 2017
·
9 min read
Business

Prothena to Report Third Quarter 2017 Financial Results on November 7

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 7.

November 1, 2017
·
1 min read
Business

Novavax to Host Conference Call to Discuss Third Quarter 2017 Financial Results on November 7, 2017

The company will report its third quarter financial and operating results following the close of U.S. financial markets.

November 1, 2017
·
1 min read
Late-Breaking REDUCE Trial Data Demonstrate Non-Inferiority of 3 vs 12 Months Dual Antiplatelet Therapy in Acute Coronary Syndrome Patients Treated With OrbusNeich’s COMBO Stent

The trial found no difference in the primary endpoint between three and 12 months DAPTin the intent to treat (ITT) population.

November 1, 2017
·
5 min read
Business

Kura Oncology to Report Third Quarter 2017 Financial Results

Management will host a webcast and conference call at 4:30 p.m. EST/1:30 p.m. PST that day to discuss the financial results and provide a corporate update.

November 1, 2017
·
1 min read
BIOPHYTIS Completes a 7.5M Euro Capital Increase to Help Accelerate Pipeline Programs in Orphan Pediatric Diseases

Since July 1st, the Company has raised a total amount of €21 M.

November 1, 2017
·
4 min read
Business

Iovance Biotherapeutics Reports Third Quarter 2017 Financial Results

The company will host a conference call at 4:30pm ET today.

November 1, 2017
·
14 min read
Business

REVA to Hold Third Quarter 2017 Financial Results Call

The call is scheduled for 2:00 p.m. US PST on Tuesday, November 7, 2017.

November 1, 2017
·
2 min read
BioCapital

Integrated Biotherapeutics Partners With CARB-X the First Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus

Integrated BioTherapeutics announced today that is has been awarded up to $168,000, with the possibility of up to $8.3M more based on the achievement of milestones, to develop the first entirely toxoid-based multivalent vaccine for the prevention of MRSA.

November 1, 2017
·
3 min read
Lexaria Bioscience Receives Groundbreaking U.S. Patent Allowance for Its DehydraTECHTM Delivery of THC, NSAIDs, Nicotine and Vitamins.

This Notice of Allowance applies to the delivery of all active pharmacological ingredients (“APIs”) Lexaria had been seeking.

November 1, 2017
·
3 min read